

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Shine Justice Ltd
<b>ABN</b> 93 162 817 905

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Sutton Bayes
<b>Date of last notice</b>	1 September 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	1 July 2024
<b>No. of securities held prior to change</b>	<b>Direct:</b> 38,312 FY24 NED Rights <b>Indirect:</b> 31,104 fully paid ordinary shares (Kateco (Vic.) Pty Ltd as trustee for the David Bayes Investment Trust) ( <b>Kateco</b> ) 70,023 fully paid ordinary shares (Pacific Custodians Pty Limited as trustee for the Non-executive Director Equity Plan ( <b>NED Equity Plan</b> ) ( <b>Trustee</b> ))
<b>Class</b>	Entitlements to acquire fully paid ordinary shares granted under the NED Equity Plan in respect of the financial year ending 30 June 2025 ( <b>FY25 NED Rights</b> )
<b>Number acquired</b>	39,094
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	The number of FY25 NED Rights granted under the NED Equity Plan is based on the amount of director fees and superannuation to be sacrificed during the participation period, divided by the volume weighted average price of Shine Justice Ltd shares on ASX on 3-21 June 2024 (inclusive) (\$0.7331). The amount of director fees and superannuation to be sacrificed by Mr Bayes is \$28,660.
<b>No. of securities held after change</b>	<b>Direct:</b> 38,312 FY24 NED Rights 39,094 FY25 NED Rights  <b>Indirect:</b> 31,104 fully paid ordinary shares (Kateco) 70,023 fully paid ordinary shares (Trustee)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of FY25 NED Rights under the NED Equity Plan in respect of the participation period 1 July 2024 – 30 June 2025

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.